Assessing Safety of OvaPrime Procedure in Women with Primary Ovarian Insufficiency or Poor Ovarian Response
OvaPrime Treatment
Maladies génito-urinaires+7
+ Maladies Génitales
+ Maladies Annexielles
Étude thérapeutique
Résumé
Date de début de l'étude : 1 octobre 2016
Date à laquelle le premier participant a commencé l'étude.This research study focuses on evaluating the safety of the OvaPrime procedure in women diagnosed with primary ovarian insufficiency (POI) or poor ovarian response (POR). The primary goal is to understand the safety aspects of this procedure in these women. POI is a condition where the ovaries stop functioning normally before the age of 40, while POR refers to a lesser than expected response to fertility medication. This study is important as it could potentially offer a new treatment option for these conditions, addressing unmet needs in women's reproductive health. A maximum of 95 women will participate in this study, with at least 30 having POI and 50 with POR. Each participant will have one ovary exposed to the EggPC cells (part of the OvaPrime procedure), while the other ovary will be exposed to the EggPC vehicle, acting as a control. This allows each participant to serve as their own control in the study. The results between the treatment and control ovary will be compared for relevant endpoints such as antral follicle counts. The study will last approximately 6 years, including enrollment, treatment, and a 5-year follow-up. The safety of the procedure will be evaluated by monitoring adverse events and serious adverse events in all subjects, regardless of pregnancy. For those who become pregnant, they will be followed through pregnancy and 1-year post-partum, with the safety of the offspring monitored up to one year post-delivery in the main study, and up to 5 years in a long-term follow-up study.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.81 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.De 21 à 45 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria: 1. Subjects who are diagnosed with EITHER POI or POR as defined below: * POI subjects who are: * \< 40 years of age * have non-detectable AMH * FSH \>15.0 mIU/ml and/or symptoms of menopause * POR (based on European Society of Human Reproduction and Embryology (ESHRE) guidelines must have two of the following: * 40 years of age * A previous IVF cycle with \< 3 oocytes with a standard of care controlled ovarian hyperstimulation protocol * An abnormal ovarian reserve test defined as: 1. AFC \< 5 - 7 follicles or 2. AMH \< 0.5 - 1.1 ng/ml or 3. Highest ever baseline FSH \> 15.0 ml U/ml 2. Subject must have both ovaries. 3. Subject agrees to participate in main study follow up as well as Long Term Follow-up (LTFU) sub-study 4. Subject's male partner or sperm donor source must meet the following requirements: * Semen must be an ejaculate (not surgically derived, epididymal, testicular, electro- ejaculated sperm), collected by ejaculation. * Male partner's testes must not have been exposed to chemotherapy. * Semen must have some morphologically normal spermatozoa according to the World Health Organization (see table below) and adequate concentration with some motile spermatozoa for insemination of all oocytes by intra-cytoplasmic sperm injection (ICSI). WHO Semen variable 2010 Volume (mL) 1.5 Concentration (106 mL-1) 15 Total sperm number (106/ejaculate) 39 Motility (% motile) 40 (a + b + c) Forward progression 32 (a + b) Morphology (% normal) 4 Viability/vitality (% live) 58 White blood cells (106 mL-1) \< 1.0 5. Partner must also agree to all research study requirements including follow up (including main study as well as LTFU sub-study) of offspring and sign consent form (not applicable in the case of a woman using sperm donation). Exclusion Criteria: 1. Subject with a diagnosis of POI who is ≥ 40 years of age or \< 21 years of age at the time of the OvaPrime procedure 2. Subject with onset of POI \< 18 years of age 3. Subject with a diagnosis of POR who is \> 45 years of age at the time of the OvaPrime procedure 4. Subject has had any prior surgery/medical condition that would prevent direct access to the ovaries (e.g., pelvic adhesions, tubo- ovarian adhesions location/displacement of the ovary(ies) or high body mass index (BMI)). 5. Subject has severe (stage IV) endometriosis or presence of an endometrioma 6. Subject has a unilateral or bilateral untreated hydrosalpinx 7. Subject has participated in the active phase of another investigational trial within the previous 30 days 8. Subject has a history of prior chemotherapy or radiation therapy to the pelvis 9. Subjects and/or partner (supplying sperm) with known karyotypic abnormalities 10. Subjects with POI who have FMR1 premutations or an FMRI mutation 11\. Subjects who are positive for the hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.Un seul groupe d'intervention est désigné dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Groupe I
Objectifs de l'étude
Objectifs principaux
Objectifs secondaires
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 1 site